Orphan drug
US designation for drugs treating rare diseases (fewer than 200,000 US patients).
Definition
Under the Orphan Drug Act (1983), drugs treating diseases affecting fewer than 200,000 patients in the US can receive orphan designation. Benefits include 7 years of market exclusivity after approval, tax credits on clinical trial costs, and waiver of PDUFA fees.